{
  "docId": "019de076-9434-73df-8e70-401e13bb3d65",
  "docSlug": "692690be0ea25b83b6a4c7490ff14999",
  "documentTitle": "BioAtla | Investor Presentation Deck | 55 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 46,
  "pageCount": 55,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes specific patient counts and clinical outcomes (responses, stable disease, progressive disease).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9434-73df-8e70-401e13bb3d65/46",
  "deckHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65",
  "deckJsonHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65.json",
  "deckAnchorHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.08,
        "y": 0.45
      },
      "kind": "list",
      "text": "We observed a total of four responses, two stable disease and two progressive disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "352ece37-1b3f-4348-8ec5-f63fd23c9c06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.08,
        "y": 0.51
      },
      "kind": "list",
      "text": "Two responses observed in ROR2 TmPS negative patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77a293aa-de2c-4059-a865-05ef0193d69f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "list",
      "text": "As of Nov 3, eight melanoma monotherapy patients are evaluable* with reported first scan data across Phase 1 and Phase 2",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0858782-447b-4b80-9573-0dc559051e3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.04,
        "y": 0.59
      },
      "kind": "list",
      "text": "Phase 2 initial data readout (n = ~20) expected in 1H 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac743e4b-a956-495e-b296-9a882308cdca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "Completed enrollment Q2W targeted cohort who previously progressed on PD-1/L1 therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f86ace6e-a640-4551-b1f9-4ee41e4268b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.1,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "*7 patients in Phase 2 received 1.8 mg/kg Q2W and 1 patient in Phase 1 received 3.0 mg/kg Q3W",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "960fb397-94e2-4011-a7fa-7a87a8abadcf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Promising early signals of efficacy - continuing to collect data in ongoing study",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a58e40e-2783-487e-8b3a-c73b288d6f58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 2 CAB-ROR2 (BA3021) in Stage IV Multi-Refractory Melanoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3316807-34c3-4b47-9902-4ff9da56f83a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}